Overview Dividends

(EVOK) Evoke Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30049G2030

Nasal Spray, Diabetic Gastroparesis

Pharmaceuticals
Market Cap in USD: 19m
IPO / Inception: 2013-09-25
Return 12m vs S&P 500: 314%

EPS (Earnings per Share)

EPS (Earnings per Share) of EVOK over the last years for every Quarter: "2020-12": -1.08, "2021-03": -0.96, "2021-06": -0.84, "2021-09": -0.72, "2021-12": -0.72, "2022-03": -0.84, "2022-06": -0.71, "2022-09": -0.6, "2022-12": -0.53, "2023-03": -0.67, "2023-06": -0.56, "2023-09": -0.51, "2023-12": -0.59, "2024-03": -0.17, "2024-06": -0.9294, "2024-09": -0.94, "2024-12": -0.77, "2025-03": -0.51, "2025-06": -0.62, "2025-09": -0.45,
EPS CAGR: 19.67%
EPS Trend: 17.5%
Last SUE: 0.00
Qual. Beats: 0

Revenue

Revenue of EVOK over the last years for every Quarter: 2020-12: 0.02302, 2021-03: 0.090421, 2021-06: 0.236635, 2021-09: 0.930449, 2021-12: 0.360571, 2022-03: 0.41838, 2022-06: 0.461795, 2022-09: 0.8321, 2022-12: 0.79637, 2023-03: 0.810408, 2023-06: 1.131368, 2023-09: 1.56286, 2023-12: 1.675994, 2024-03: 1.73549, 2024-06: 2.551366, 2024-09: 2.654186, 2024-12: 3.308373, 2025-03: 3.080158, 2025-06: 3.752142, 2025-09: 4.283979,
Rev. CAGR: 93.48%
Rev. Trend: 98.6%
Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 161%
Value at Risk 5%th 171%
Relative Tail Risk -35.77%
Reward TTM
Sharpe Ratio 1.35
Alpha 396.18
CAGR/Max DD -0.13
Character TTM
Hurst Exponent 0.459
Beta 0.413
Beta Downside -0.139
Drawdowns 3y
Max DD 97.00%
Mean DD 82.59%
Median DD 90.56%

Description: EVOK Evoke Pharma December 31, 2025

Evoke Pharma, Inc. (NASDAQ:EVOK) is a specialty pharmaceutical firm that develops and commercializes treatments for gastro-enterological disorders. Its lead product, Gimoti-a metoclopramide nasal spray-targets acute and recurrent diabetic gastroparesis in adults, and the company distributes primarily to gastroenterologists, internal medicine specialists, primary-care physicians, and select health-care providers. As of December 15 2025, Evoke operates as a subsidiary of QOL Medical, LLC, after being incorporated in 2007 and headquartered in Solana Beach, California.

Key performance indicators as of the latest quarter (Q3 2025) show a market capitalization of roughly $30 million, cash and cash equivalents of $12 million, and a net loss of $4.2 million, reflecting a burn rate of about $1.4 million per month. The company’s pipeline remains thin, with Gimoti as the sole commercial product and a Phase 2 trial underway for a delayed-release formulation of the same molecule. The gastro-enterology market is buoyed by an aging U.S. population and an estimated 4 % prevalence of gastroparesis among diabetics, driving modest but steady demand for niche therapies.

For a deeper quantitative look at EVOK’s valuation metrics and peer comparison, the ValueRay platform provides a concise data snapshot worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-5.23m TTM) > 0 and > 6% of Revenue (6% = 865.5k TTM)
FCFTA -0.21 (>2.0%) and ΔFCFTA 16.38pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 22.85% (prev 49.57%; Δ -26.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.21 (>3.0%) and CFO -3.32m > Net Income -5.23m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 1.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (2.56m) change vs 12m ago 82.69% (target <= -2.0% for YES)
Gross Margin 97.02% (prev 96.55%; Δ 0.47pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 96.80% (prev 60.88%; Δ 35.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.21 (EBITDA TTM -4.73m / Interest Expense TTM 500.0k) >= 6 (WARN >= 3)

Altman Z'' -38.14

(A) 0.21 = (Total Current Assets 15.5m - Total Current Liabilities 12.2m) / Total Assets 15.6m
(B) -8.49 = Retained Earnings (Balance) -132.8m / Total Assets 15.6m
warn (B) unusual magnitude: -8.49 — check mapping/units
(C) -0.07 = EBIT TTM -1.10m / Avg Total Assets 14.9m
(D) -10.81 = Book Value of Equity -132.8m / Total Liabilities 12.3m
Total Rating: -38.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.90

1. Piotroski 2.50pt
2. FCF Yield -26.63%
3. FCF Margin -23.05%
4. Debt/Equity 1.52
5. Debt/Ebitda 1.37
6. ROIC - WACC (= -14.94)%
7. RoE -101.4%
8. Rev. Trend 98.60%
9. EPS Trend 17.47%

What is the price of EVOK shares?

As of January 07, 2026, the stock is trading at USD 22.40 with a total of 1,101,501 shares traded.
Over the past week, the price has changed by +1.82%, over one month by +104.94%, over three months by +378.63% and over the past year by +386.96%.

Is EVOK a buy, sell or hold?

Evoke Pharma has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy EVOK.
  • Strong Buy: 0
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the EVOK price?

Issuer Target Up/Down from current
Wallstreet Target Price 18 -19.6%
Analysts Target Price 18 -19.6%
ValueRay Target Price 25.6 14.2%

EVOK Fundamental Data Overview January 05, 2026

Market Cap USD = 18.9m (18.9m USD * 1.0 USD.USD)
P/S = 1.3135
P/B = 5.6351
P/EG = -0.1
Beta = -0.136
Revenue TTM = 14.4m USD
EBIT TTM = -1.10m USD
EBITDA TTM = -4.73m USD
Long Term Debt = 112.3k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.07m USD (from shortTermDebt, last quarter)
Debt = 5.11m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.46m USD (from netDebt column, last quarter)
Enterprise Value = 12.5m USD (18.9m + Debt 5.11m - CCE 11.6m)
Interest Coverage Ratio = -2.21 (Ebit TTM -1.10m / Interest Expense TTM 500.0k)
FCF Yield = -26.63% (FCF TTM -3.32m / Enterprise Value 12.5m)
FCF Margin = -23.05% (FCF TTM -3.32m / Revenue TTM 14.4m)
Net Margin = -36.23% (Net Income TTM -5.23m / Revenue TTM 14.4m)
Gross Margin = 97.02% ((Revenue TTM 14.4m - Cost of Revenue TTM 429.8k) / Revenue TTM)
Gross Margin QoQ = 97.62% (prev 95.53%)
Tobins Q-Ratio = 0.80 (Enterprise Value 12.5m / Total Assets 15.6m)
Interest Expense / Debt = 2.47% (Interest Expense 126.0k / Debt 5.11m)
Taxrate = 21.0% (US default 21%)
NOPAT = -871.6k (EBIT -1.10m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.27 (Total Current Assets 15.5m / Total Current Liabilities 12.2m)
Debt / Equity = 1.52 (Debt 5.11m / totalStockholderEquity, last quarter 3.36m)
Debt / EBITDA = 1.37 (negative EBITDA) (Net Debt -6.46m / EBITDA -4.73m)
Debt / FCF = 1.94 (negative FCF - burning cash) (Net Debt -6.46m / FCF TTM -3.32m)
Total Stockholder Equity = 5.15m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.39% (Net Income -5.23m / Total Assets 15.6m)
RoE = -101.4% (Net Income TTM -5.23m / Total Stockholder Equity 5.15m)
RoCE = -20.95% (EBIT -1.10m / Capital Employed (Equity 5.15m + L.T.Debt 112.3k))
RoIC = -8.58% (negative operating profit) (NOPAT -871.6k / Invested Capital 10.2m)
WACC = 6.35% (E(18.9m)/V(24.1m) * Re(7.54%) + D(5.11m)/V(24.1m) * Rd(2.47%) * (1-Tc(0.21)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -12.54%
Fair Price DCF = unknown (Cash Flow -3.32m)
EPS Correlation: 17.47 | EPS CAGR: 19.67% | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.60 | Revenue CAGR: 93.48% | SUE: -0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=0.68 | Chg30d=+0.040 | Revisions Net=+1 | Growth EPS=+136.2% | Growth Revenue=+58.0%

Additional Sources for EVOK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle